- Home
- ILMN vs BIIB Comparison
ILMN vs BIIB Comparison
Compare ILMN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILMN
- BIIB
- Stock Information
- Founded
- ILMN 1998
- BIIB 1978
- Country
- ILMN United States
- BIIB United States
- Employees
- ILMN N/A
- BIIB N/A
- Industry
- ILMN Medical Specialities
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ILMN Health Care
- BIIB Health Care
- Exchange
- ILMN Nasdaq
- BIIB Nasdaq
- Market Cap
- ILMN 23.6B
- BIIB 25.1B
- IPO Year
- ILMN 2000
- BIIB 1991
- Fundamental
- Price
- ILMN $135.21
- BIIB $149.02
- Analyst Decision
- ILMN Buy
- BIIB Buy
- Analyst Count
- ILMN 17
- BIIB 26
- Target Price
- ILMN $163.12
- BIIB $248.00
- AVG Volume (30 Days)
- ILMN 2.3M
- BIIB 1.6M
- Earning Date
- ILMN 02-06-2025
- BIIB 02-11-2025
- Dividend Yield
- ILMN N/A
- BIIB N/A
- EPS Growth
- ILMN N/A
- BIIB 10.05
- EPS
- ILMN N/A
- BIIB 11.06
- Revenue
- ILMN $4,390,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- ILMN N/A
- BIIB N/A
- Revenue Next Year
- ILMN $4.05
- BIIB N/A
- P/E Ratio
- ILMN N/A
- BIIB $13.47
- Revenue Growth
- ILMN N/A
- BIIB N/A
- 52 Week Low
- ILMN $97.36
- BIIB $145.07
- 52 Week High
- ILMN $156.66
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- ILMN 40.42
- BIIB 32.44
- Support Level
- ILMN $130.31
- BIIB $145.07
- Resistance Level
- ILMN $137.69
- BIIB $149.92
- Average True Range (ATR)
- ILMN 5.31
- BIIB 3.81
- MACD
- ILMN -1.10
- BIIB 0.05
- Stochastic Oscillator
- ILMN 22.85
- BIIB 22.51
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.